Ark Biopharmaceutical (ArkBio) says it has successfully dosed all participants in a Phase I clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infection. 

The treatment offers a potential a new option for preventing RSV infection for vulnerable infants susceptible to RSV. 

RSV is a globally prevalent and highly contagious RNA virus known for its seasonal epidemic patterns.  

It is one of the primary pathogens responsible for lower respiratory tract infections in children under five years worldwide and the leading cause of hospitalisation among infants under one year of age. 

AK0610 is a monoclonal antibody targeting the pre-fusion F protein of RSV that was isolated from a recovered infant and engineered.  

Compared to other RSV-neutralising antibodies, AK0610 has a unique viral antigen binding epitope and novel mechanism of action. According to the company, in preclinical studies, AK0610 demonstrated outstanding viral neutralisation activity and an extended half-life that offers prolonged protection. 

Most of the Phase I study participants have been followed for up to six months with no observed serious adverse events related to the drug and drug exposure reaching the anticipated effective protective concentration. 

Dr Jim Wu, CEO of ArkBio, stated: “The successful enrollment and dosing completion of all participants in Phase I clinical trial of AK0610 represents a significant step forward for ArkBio in the area of RSV prevention. Based on the current Phase I clinical data, we are encouraged that AK0610 will become a new generation, long-acting monoclonal antibody for RSV prevention. Prevention and treatment of RSV infection complement each other, especially for high-risk populations like infants, the elderly, and immunocompromised patients.”

Diana Spencer, Senior Digital Content Editor, DDW